PCAC July 23-24 Hearing: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon Under Review
On July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee meets at the agency's White Oak Campus to evaluate seven peptides for inclusion on the 503A bulks list. The decision affects whether licensed compounding pharmacies can legally dispense these peptides under physician prescriptions.
Meeting overview
The FDA announced in April 2026 that the Pharmacy Compounding Advisory Committee (PCAC) would convene on July 23-24 to evaluate seven peptide nominations for the 503A bulks list. The meeting will be held at FDA's White Oak Campus in Silver Spring, Maryland, with virtual attendance options. The committee will hear nominator presentations, accept comments through open public hearing sessions, deliberate on the evidence, and vote a recommendation to FDA.
The PCAC vote is advisory, not binding. After the meeting, the FDA reviews the recommendation and decides whether to initiate rulemaking to formally add a substance to the 503A bulks list. Even a unanimous positive vote on July 24 does not legalize compounding immediately. Rulemaking typically takes six to twelve months. Negative votes generally end the current nomination, though substances can be re-nominated in future cycles.
Update — late June 2026: FDA briefing materials recommend against all seven
Ahead of the meeting, FDA career scientists posted briefing materials concluding that the evidence does not support adding any of the seven peptides to the 503A bulks list. Reporting from NPR, U.S. News, and Medical Xpress in late June and early July 2026 describes agency reviewers flagging insufficient safety and effectiveness data for BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. The staff position is a recommendation to the committee, not a final vote, but it sets a steep evidence bar for nominators on July 23-24.
Status check — July 15, 2026: one week out
With eight days to the meeting, the agenda published by FDA is unchanged: four peptides on July 23 (BPC-157, KPV, TB-500, MOTS-c) and three on July 24 (DSIP/emideltide, Semax, Epitalon). The staff briefing materials recommending against all seven remain the most recent formal agency position on the record, and no nominator has publicly withdrawn. The open public hearing docket is the last remaining input before the committee deliberates. Anyone planning to comment should treat this week as the practical deadline rather than the meeting date itself.
The advisory panel reshuffle
The makeup of the committee itself has become part of the story. Earlier versions of PCAC were dominated by academic pharmacologists from universities including Duke, Harvard, and Johns Hopkins, and those panels repeatedly voted against adding peptide ingredients to compounding lists. Under HHS Secretary Robert F. Kennedy Jr., the panel weighing these seven peptides has been reshaped to include practitioners who run peptide clinics, sell peptide injections, or promote the substances publicly. That creates a direct tension: FDA staff on record against the peptides, a panel weighted toward access, and a final decision that still rests with the agency after the vote.
For patients and prescribers, the practical read is that the outcome is less predictable than a normal PCAC cycle. A panel sympathetic to compounding access could vote to recommend one or more peptides over staff objections. FDA leadership would then decide whether to follow the panel or its own reviewers. Either path still runs through months of rulemaking before anything changes at the pharmacy counter.
Day-by-day schedule
| Day | Peptide | Nominated use | Existing site coverage |
|---|---|---|---|
| July 23 | BPC-157 | Ulcerative colitis | BPC-157 benefits |
| KPV | Wound healing, inflammatory conditions | KPV peptide | |
| TB-500 | Wound healing | TB-500 dosage | |
| MOTS-c | Obesity, osteoporosis | MOTS-c peptide | |
| July 24 | DSIP (emideltide) | Opioid withdrawal, chronic insomnia, narcolepsy | DSIP peptide |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Semax peptide | |
| Epitalon | Insomnia | Epitalon benefits |
BPC-157: the highest-profile nomination
BPC-157 is the most widely used peptide on the July 23 schedule. The nomination is specifically for ulcerative colitis, a narrower indication than the broader gut-healing use cases the peptide is associated with in the wellness market. The committee will evaluate whether the available clinical and preclinical evidence supports the safety and effectiveness of compounded BPC-157 for ulcerative colitis. Most of the existing literature is preclinical and rodent-model based, with limited controlled human data, though case series and observational reports exist.
A favorable PCAC recommendation does not legalize BPC-157 for general use. It would create a pathway specifically for ulcerative colitis prescriptions through compounding pharmacies. Off-label use would still be possible but would expose prescribers to greater scrutiny. See our guides on BPC-157 for gut healing, BPC-157 dosage, and BPC-157 side effects for the existing clinical picture. For where the peptide stands right now, see BPC-157 FDA status in 2026.
KPV: short tripeptide with the strongest evidence base
KPV (lysine-proline-valine) is a tripeptide derived from alpha-melanocyte stimulating hormone. It has a relatively narrow molecular profile, a clean preclinical safety record, and meaningful published literature for inflammatory bowel disease and inflammatory skin conditions. The nomination for wound healing and inflammatory conditions is broader than the strongest evidence base supports, which may complicate the vote.
KPV is one of the two peptides on the July 23 schedule with the most plausible path to a favorable recommendation, alongside BPC-157. See our coverage on KPV for gut health, KPV benefits, and KPV dosage.
TB-500: long compounding history, mixed evidence
TB-500 (a synthetic fragment of thymosin beta-4) has a long history in the peptide compounding market for soft-tissue repair. The clinical evidence in humans is weaker than BPC-157 or KPV, leaning heavily on preclinical models and athlete anecdote. The nominated use is wound healing, which may stretch the evidence beyond what controlled studies support.
The committee may struggle with the gap between widespread compounding use and limited rigorous evidence. A negative vote here would not be surprising. See our guides on TB-500 dosage, BPC-157 vs TB-500, and the BPC-157 + TB-500 blend for clinical context.
MOTS-c: novel mitochondrial peptide, thin clinical data
MOTS-c is a mitochondrial-derived peptide with active preclinical research for metabolic disease and aging. The nominated uses, obesity and osteoporosis, both have indirect evidence from animal models but limited controlled human trials. The committee will likely flag the evidence gap.
MOTS-c sits in the early-stage research category where compounding approval is harder to justify without more human safety and efficacy data. See our MOTS-c peptide overview and MOTS-c dosage for the current state of the literature.
Day 2: DSIP, Semax, Epitalon
The July 24 substances all have decades of use, mostly in Eastern European and Russian medical practice, but limited Western controlled trial data. The FDA assesses substances primarily on the global evidence base and on safety, but bias toward Western trial designs creates an evidence-quality bar that these three may struggle to meet.
- DSIP (delta sleep-inducing peptide, emideltide): The uses FDA evaluated are opioid withdrawal, chronic insomnia, and narcolepsy. Mechanism is plausible but human RCT data is thin. See our DSIP peptide guide.
- Semax: The uses FDA evaluated are cerebral ischemia, migraine, and trigeminal neuralgia; the peptide is better known in the wellness market for cognitive enhancement. US-language clinical data is limited. See Semax peptide and Semax vs Selank.
- Epitalon: The use FDA evaluated is insomnia, though the peptide is marketed for longevity. Those longevity claims rely on aging cohort studies from a single research group, which is a structural evidence weakness. See Epitalon benefits.
How to submit a public comment
Each substance has its own docket. To submit comment:
- Go to regulations.gov and open docket FDA-2025-N-6895, the docket for the July 23-24, 2026 PCAC meeting.
- Deadline: submit by July 9, 2026 to have your comment formally distributed to committee members ahead of the meeting. Later comments still enter the public record but may miss the members.
- Submit comment to the relevant peptide docket. Comments addressed to the general PCAC docket are less effective.
- Specific clinical case material, peer-reviewed evidence, and detailed safety data carry more weight than general expressions of support.
- If you want to speak during the open public hearing, sign up in advance through the meeting registration link in the Federal Register notice. Slots are limited.
What to watch on the day
Three signals to track during the meeting:
- Committee composition: PCAC members rotate. The clinical pharmacology and compounding pharmacy members tend to be more sympathetic to compounding access. Industry representatives and FDA staff tend to apply stricter evidence criteria.
- Nominator presentations: The strength of the case made by each nominator predicts the vote more than any other variable. Well-prepared nominators with detailed clinical evidence outperform weaker presentations regardless of peptide popularity.
- Tie votes and abstentions: A close vote with multiple abstentions usually signals the FDA will request additional information rather than rule definitively.
Related regulatory actions
The PCAC hearing is one of three concurrent peptide regulatory threads:
- The April 2025 reclassification of 14 peptides from Category 2 to Category 1. See which 14 peptides are legal again in 2026.
- The May 2026 FDA proposed rule excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. See FDA 503B GLP-1 exclusion.
- The ongoing FDA enforcement against research peptide vendors marketing for human use. See FDA peptide ban.
- Peptides that were not nominated stay exactly where they are, regardless of how this vote goes. Kisspeptin is a useful example: a well-characterized peptide with a real clinical trial program that is not on any bulks-list pathway and has no scheduled review.
Bottom line
The July 23-24 hearing is the most significant peptide regulatory event of 2026 on the access side. A favorable PCAC recommendation for BPC-157 or KPV would open a legal compounding pathway for tens of thousands of patients currently buying research-grade peptides through the gray market. A negative recommendation pushes those patients further into channels with no quality controls or physician oversight. With FDA staff now on record against all seven and the advisory panel reshaped toward compounding access, the vote is genuinely hard to call. The realistic range runs from a clean sweep of negative recommendations that tracks staff guidance, to a split where a sympathetic panel backs BPC-157 or KPV over staff objections. Even a favorable vote triggers FDA rulemaking that would stretch well into 2027 before any peptide becomes legally compoundable.
Sources
Frequently Asked Questions About PCAC peptides
Not formally. In late June 2026, FDA career scientists posted briefing materials recommending that none of the seven peptides be added to the 503A bulks list, citing insufficient safety and effectiveness evidence. That is a staff recommendation to the advisory committee, not a binding decision. The PCAC still meets July 23-24 to hear nominators, take public comment, and vote. The FDA makes the final call afterward, and it can side with either its reviewers or the committee.
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that recommends which bulk drug substances should be added to the 503A bulks list. The July 23-24, 2026 meeting at FDA White Oak in Silver Spring, Maryland will evaluate seven peptides. Day 1 covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 covers DSIP (also called emideltide), Semax, and Epitalon. The meeting includes nominator presentations, open public hearing sessions, and committee deliberation.
Section 503A allows licensed compounding pharmacies to compound drugs for individual patients with a valid prescription. To use a bulk drug substance that is not an FDA-approved drug ingredient and is not on a USP monograph, the substance must appear on the 503A bulks list. Adding a peptide to the list creates a legal pathway for compounding pharmacies to dispense it under a physician prescription. Without the listing, compounding from bulk is not permitted under 503A, though limited supply through research-only channels continues to exist in a gray area.
No. PCAC is advisory. The committee votes on each substance and submits a recommendation to FDA. The FDA can accept, modify, or reject the recommendation. If the FDA accepts a recommendation to add a substance to the bulks list, it must initiate a formal rulemaking process to amend the list, which takes months to a year. So a positive PCAC vote on July 23-24 is necessary but not sufficient for any peptide to become legally compoundable.
Predicting committee votes is difficult, but the peptides with the strongest combined evidence and lower safety concerns are KPV and BPC-157, both of which have meaningful clinical and preclinical literature for inflammation and tissue repair. TB-500 has weaker controlled clinical data but a long compounding history. MOTS-c, DSIP, Semax, and Epitalon have thinner clinical evidence and broader safety questions. The committee tends to weight evidence quality more heavily than usage prevalence, so historical compounding popularity does not automatically translate to a favorable recommendation.
The nominations specify intended clinical uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, DSIP (emideltide) for opioid withdrawal, chronic insomnia, and narcolepsy; Semax for cerebral ischemia, migraine, and trigeminal neuralgia; and Epitalon for insomnia. The PCAC evaluates whether the bulk substance, used for the nominated clinical purpose, can be safely and effectively compounded. Approval for the listed use does not automatically extend to other uses.
The April 2025 reclassification of 14 peptides from Category 2 back to Category 1 was a separate FDA action that resolved an earlier import-alert-style restriction. The July 2026 PCAC hearing is the next step in evaluating whether specific peptides should have a legal 503A pathway. Some peptides on the 14-peptide list are also under PCAC review. The two processes work in parallel: Category 1 status reduces customs interdiction risk for research-grade supply, while a 503A bulks list addition creates a legal pharmacy compounding pathway. See our guide on the 14 peptides becoming legal again for the broader context.
Yes. The meeting will be held at FDA White Oak Campus, Silver Spring, Maryland, with virtual attendance options. Written comments go to the public docket FDA-2025-N-6895 on regulations.gov. To be formally provided to committee members before the meeting, comments must be submitted by July 9, 2026; comments after that date still enter the record but may not reach members in time. Open public hearing speaking slots are limited and require advance sign-up. Detailed clinical case material and peer-reviewed evidence carry more weight than generic support statements.
The 503A bulks list governs compounding by traditional pharmacies for individual patients with a prescription. The 503B bulks list governs compounding by outsourcing facilities that ship at larger scale without patient-specific prescriptions. The July 2026 PCAC hearing covers the 503A list. The May 2026 FDA proposed rule excluding GLP-1s from the 503B bulks list covers a different list with a different statutory framework. See our FDA 503B GLP-1 exclusion guide for the GLP-1 side of the regulatory picture.
A rejection ends the current attempt to add the substance to the 503A bulks list. The peptide can be re-nominated in a future PCAC cycle if new evidence emerges. Rejection does not change the legal status of research-grade supply, which operates under different rules entirely. It also does not affect over-the-counter dietary supplement availability where the peptide is not banned from supplements. Practical access continues through existing channels, but the legal pharmacy compounding pathway remains closed for that substance.
Short term, the hearing itself does not change anything. Current research-grade supply will continue at current pricing. If a peptide is recommended by PCAC and the FDA initiates rulemaking, formal listing takes another six to twelve months. At that point, compounding pharmacies can dispense the peptide legally and prices may rise to reflect pharmacy-grade quality control and physician oversight. Research-grade supply at lower prices typically continues in parallel but with the same gray-area legal exposure as today.